See leaflet
Nianeb®
neratinib
Indications
- Prolonged adjuvant treatment of early-stage breast cancer with hormone receptor positive and HER2 overexpression/amplification, who have completed prior adjuvant treatment based on Trastuzumab less than a year ago.
Presentations
- 40 mg x 180 tablets
- 40 mg x 180 tablets